AWM Investment Company Inc. Acquires New Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

AWM Investment Company Inc. acquired a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 106,435 shares of the company's stock, valued at approximately $462,000. AWM Investment Company Inc. owned about 0.21% of Cardiff Oncology at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in Cardiff Oncology in the 4th quarter worth about $25,000. Thoroughbred Financial Services LLC lifted its stake in shares of Cardiff Oncology by 43.8% in the fourth quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock worth $85,000 after buying an additional 5,970 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Cardiff Oncology by 12.8% in the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after buying an additional 6,140 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Cardiff Oncology by 38.1% during the fourth quarter. Wells Fargo & Company MN now owns 32,064 shares of the company's stock valued at $139,000 after buying an additional 8,851 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Cardiff Oncology by 17.9% during the fourth quarter. Barclays PLC now owns 62,596 shares of the company's stock valued at $272,000 after acquiring an additional 9,507 shares in the last quarter. 16.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright upped their price objective on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

Cardiff Oncology Stock Performance

CRDF opened at $3.07 on Wednesday. The stock has a market capitalization of $204.23 million, a P/E ratio of -3.27 and a beta of 1.81. The company's 50-day simple moving average is $2.99 and its two-hundred day simple moving average is $3.46. Cardiff Oncology, Inc. has a 52-week low of $2.01 and a 52-week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.09 million. Research analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.